Skip to content

Therapeutic effect of Parkinson's disease based on lifestyle medicine intervention

Therapeutic effect of Parkinson's disease based on lifestyle medicine intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124128
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-02-28
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Lifestyle medicine intervention:Develop a lifestyle medicine prescription, including nutritional intervention, physical activity, stress management, sleep management, smoking cessation and alcohol res
Traditional treatment control group:Traditional treatment

Sponsors

Shanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 40 to 70 years old; 2. Patients with clinically confirmed or highly probable Parkinson’s disease who meet the Chinese Diagnostic Criteria for Parkinson’s Disease (2016); 3. In the on-phase of medication, with Hoehn-Yahr (H-Y) stage <= 2.5; 4. Able to cooperate well with lifestyle intervention measures; 5. The subjects and/or their legal representatives have a full understanding of the trial content, voluntarily sign the informed consent form, and agree to complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed with Parkinsonism other than idiopathic Parkinson’s disease, or those with an unclear diagnosis; 2. A history of stroke or intracranial space-occupying lesions; 3. A history of ophthalmic diseases affecting eye movements; 4. Any neurological diseases or musculoskeletal injuries (such as fractures, stroke sequelae, etc.) that interfere with gait or balance, other than the motor symptoms of Parkinson’s disease; 5. Patients with mental illnesses or those unable to cooperate for other reasons (including but not limited to: dementia, a score of = 23 on the Mini-Mental State Examination); 6. Other circumstances: Uncontrollable factors.

Design outcomes

Primary

MeasureTime frame
Movement Disorder Society - Unified Parkinson's Disease Rating Scale(MDS-UPDRS);

Secondary

MeasureTime frame
Hamilton Depression Rating Scale;Hamilton Anxiety Rating Scale;Mini-Mental State Examination(MMSE);Functional Magnetic Resonance Imaging (fMRI);Parkinson’s Disease Sleep Scale-2(PDSS-2);Montreal Cognitive Assessment (MoCA);Activities of Daily Living, ADL;EyeKnow Neuromental Health Assessment;Quality of Life in Patients with Parkinson's Disease-39;

Countries

China

Contacts

Public ContactBai Xue

Shanxi Provincial People's Hospital

Doctor_BX@163.com+86 351 4960050

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026